Tuesday - May 13, 2025
Kalamazoo, Michigan, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2023 Wells Fargo Securities Healthcare Conference on Thursday, September 7, 2023.
Glenn Boehnlein, Vice President, Chief Financial Officer and Jason Beach, Vice President, Investor Relations will represent the Company in a presentation scheduled for 3:00 p.m. Eastern Time.
A simultaneous webcast and replay of the Company's presentation will be available on Stryker's website at www.stryker.com. The webcast will be archived on the Investor Relations page of this site.
About Stryker
Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Medical and Surgical, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at www.stryker.com.
Contacts
For investor inquiries please contact:
Jason Beach, Vice President, Investor Relations at 269-385-2600 or jason.beach@stryker.com
For media inquiries please contact:
Yin Becker, Vice President, Chief Corporate Affairs Officer at 269-385-2600 or yin.becker@stryker.com
Last Trade: | US$388.08 |
Daily Change: | 7.16 1.88 |
Daily Volume: | 1,314,642 |
Market Cap: | US$147.940B |
May 01, 2025 March 04, 2025 March 03, 2025 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load